Ryvu Therapeutics S.A.

Research and experimental development in natural sciences and engineering

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2010-10-06
Share capital
9,248,059.20 PLN
Activity description

RYVU Therapeutics is a clinical-stage biopharmaceutical company developing novel small-molecule therapies for precision oncology. Its pipeline includes RVU305 for MTAP-deleted tumors, romaciclib (RVU120) for R/R AML, myelofibrosis and LR-MDS, and dapolsertib for DLBCL. The company runs clinical studies and advances programs in kinase, synthetic lethality, and immuno-oncology pathways.

Registered address
ul. Leona Henryka Sternbacha 2, 30-394 Kraków, Poland
Website
Email
Electronic delivery address
AE:PL-89571-20056-VTTUV-14

Financials

Revenue history (in m)

Filing timeliness

Financial statements were filed on time, on average 10 days early. All were audited by a statutory auditor.

  • 202530/06/2026
  • 202401/07/2025
  • 202309/07/2024
  • 202207/07/2023
  • 202114/07/2022
  • 202029/09/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Stock quotes

PLN 17.00
-0.60 (-3.41%)
17.0017.2017.4017.0010:0012:0014:0016:00
Open
PLN 17.50
High
PLN 17.50
Low
PLN 16.90
Volume
11.6K
Avg. vol.
15.47K
Market cap
PLN 393.04M
P/E ratio
–
EPS
-PLN 2.94
Shares outstanding
23.12M
52-week
PLN 16.00 – 18.14
Dividend yield
–
Dividend
–
Ex dividend date
–
Exchange
GPW Main Market

Quarterly results

PeriodRevenueEBITNet profit
Q2 2026USD 3.24mUSD -4.52mUSD -3.53m
Q1 2026USD 4.58mUSD -3.35mUSD -3.42m
Q4 2025USD 4.52mUSD -4.22mUSD -4.42m
Q3 2025USD 3.75mUSD -6.38mUSD -6.20m

Results for Q3 2026:Nov 19, 2026

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Top 4.1%
City · Kraków325 / 16,145
Top 2.0%
Voivodeship · Małopolskie667 / 27,724
Top 2.4%
Country · Poland8,554 / 297,069
Top 2.9%

Results vs industry

Revenue
This companyUSD 25.87mMedianUSD 153.26kAverageUSD 4.77m
Net profit
This companyUSD -25.42mMedianUSD -293.45AverageUSD 306.55k
Operating costs
This companyUSD 46.31mMedianUSD 188.47kAverageUSD 4.59m
Assets
This companyUSD 56.36mMedianUSD 281.58kAverageUSD 8.35m

Public procurement

3 tenders recorded as contractor: 2 national ($3,202) and 1 EU ($468,067).

SubjectAmount
ZP/CZD/062/26 Supply of the investigational medicinal product romaciclib (RVU 120) for use in the non-commercial MEDWAY clinical trial “Phase I study of the use of the CDK8 inhibitor RVU120 in combination with everolimus in children with relapsed or progressive group 3 or 4 medulloblastoma”
$468.1K
Syllabus consultations to modify the first- and second-cycle Biology programmes and the second-cycle Natural Resources Management programme – “Key to the future-Kompleksowy program rozwoju kształcenia na potrzeby branż kluczowych UJ-22 cz.”
$3,017
Syllabus consultations to modify the first- and second-cycle Biology programmes and the second-cycle Natural Resources Management programme – “Key to the future-Kompleksowy program rozwoju kształcenia na potrzeby branż kluczowych UJ-22 cz.”
$185

Authorized Representatives

Bartłomiej Konicki age 41 – Attorney-in-fact (joint)
Krzysztof Daniel Brzózka age 47 – Vice President of the Management Board
Franz Hendrik Nogai – Management Board Member
Jakub Jan Janowski age 40 – Attorney-in-fact (joint)
Justyna Katarzyna Żółtek age 36 – Management Board Member

Manner of representation

In the case of a multi-member management board, two members of the management board acting jointly, or a member of the management board acting jointly with one of the joint commercial proxies, are authorized to represent the company.

Supervisory board

Rafał Piotr Chwast age 55 – Supervisory Board Member
Scott Fields – Supervisory Board Member
Peter Smith – Supervisory Board Member
Piotr Romanowski age 57 – Supervisory Board Member
Tadeusz Wesołowski age 75 – Supervisory Board Member

Beneficial owners

Ryvu Therapeutics is a public company listed on the Warsaw Stock Exchange, so it does not report beneficial owners to the CRBR (Art. 58 of the Polish AML Act). Its shareholders are disclosed in stock-exchange reports.

Bank accounts

Registered as a VAT taxpayer on 2007-08-10.

Debt

No entries in the National Debtors Register (KRZ).

MSiG notices

Publication dateEvent
Jun 13, 2011Shareholders' meeting convened

Public aid

53 public aid cases recorded, with a total value of $86,209,007.

PurposeGross amount
Aid for research and development projects: industrial research
$3.1M
Aid for research and development projects: experimental development
$2.3M
Aid for research and development projects: industrial research
$2.5M

European Funds

4 projects recorded: 3 from FE lists ($14,123,711) and 1 Commission grant (FTS) ($0).

ProjectEU co-financing
PERO – Predictive Engineering for Rational Oncology: functional mapping of therapeutic targets in oncology.
$5M
ONCO Prime: new possibilities for personalized cancer therapy based on primary cell culture from patients, omics characterization and functional testing.
$6.3M
A new targeted therapy for cancers with MTAP gene deletion – phase II.
$2.8M

Regulatory authorisations

AuthorityTypeStatus
Waste generation Active

Competitors

Name
Selvita S.A.
Sieć Badawcza Łukasiewicz - Port Polski Ośrodek Rozwoju Technologii Research institute
Ardigen S.A.
Jagiellońskie Centrum Innowacji sp. z o.o.
Kapadi sp. z o.o.
Farmepo sp. z o.o.
JJP Biologics sp. z o.o.
Proacta S.A.
Aronpharma sp. z o.o.
Poltreg S.A.

Change history

DateEvent
2023-01-17Share capital increase
2020-10-09Address change
2020-08-18Share capital increase
2019-10-01Name change
2018-03-16Share capital increase

FAQ

Last updated: 2026-10-07